RANI – rani therapeutics holdings, inc. - class a (US:NASDAQ)
Stock Stats
News
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Rani Therapeutics to Participate in the Evercore Healthcare Conference
Form 8-K Rani Therapeutics Holdin For: Dec 31
Form DEF 14C Rani Therapeutics Holdin For: Dec 05
Form EFFECT Rani Therapeutics Holdin
Form 424B5 Rani Therapeutics Holdin
Form PRE 14C Rani Therapeutics Holdin For: Nov 25
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.